NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 237 filers reported holding NEKTAR THERAPEUTICS in Q1 2021. The put-call ratio across all filers is 0.96 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $46 | -25.8% | 77,858 | -27.4% | 0.00% | – |
| Q2 2023 | $62 | -50.0% | 107,236 | -39.4% | 0.00% | -100.0% |
| Q1 2023 | $124 | +22.8% | 176,969 | +297.8% | 0.00% | 0.0% |
| Q4 2022 | $101 | -99.9% | 44,491 | +110.1% | 0.00% | 0.0% |
| Q3 2022 | $68,000 | -83.5% | 21,172 | -80.5% | 0.00% | -75.0% |
| Q2 2022 | $413,000 | +1.0% | 108,560 | +43.1% | 0.00% | +33.3% |
| Q1 2022 | $409,000 | -55.6% | 75,838 | +47.8% | 0.00% | -25.0% |
| Q3 2021 | $922,000 | -27.9% | 51,312 | -31.1% | 0.00% | -33.3% |
| Q2 2021 | $1,278,000 | +45.4% | 74,450 | +69.4% | 0.01% | +20.0% |
| Q1 2021 | $879,000 | -50.1% | 43,942 | -57.6% | 0.01% | -44.4% |
| Q4 2020 | $1,761,000 | +393.3% | 103,567 | +381.1% | 0.01% | +350.0% |
| Q3 2020 | $357,000 | -66.1% | 21,528 | -52.6% | 0.00% | -77.8% |
| Q2 2020 | $1,052,000 | +133.3% | 45,430 | +79.9% | 0.01% | +125.0% |
| Q1 2020 | $451,000 | -54.9% | 25,258 | -45.5% | 0.00% | -55.6% |
| Q4 2019 | $1,000,000 | -13.2% | 46,340 | -26.7% | 0.01% | 0.0% |
| Q3 2019 | $1,152,000 | -29.0% | 63,251 | +38.6% | 0.01% | -18.2% |
| Q2 2019 | $1,623,000 | -66.8% | 45,629 | -68.6% | 0.01% | -75.6% |
| Q1 2019 | $4,888,000 | +1095.1% | 145,488 | +1069.2% | 0.04% | +1025.0% |
| Q4 2018 | $409,000 | -85.6% | 12,443 | -73.2% | 0.00% | -81.0% |
| Q3 2018 | $2,833,000 | +33.1% | 46,465 | +6.6% | 0.02% | +10.5% |
| Q2 2018 | $2,128,000 | -14.3% | 43,584 | +86.5% | 0.02% | -5.0% |
| Q1 2018 | $2,484,000 | +311.3% | 23,375 | +131.0% | 0.02% | +233.3% |
| Q4 2017 | $604,000 | -22.6% | 10,118 | -68.9% | 0.01% | -14.3% |
| Q3 2017 | $780,000 | +131.5% | 32,484 | +88.7% | 0.01% | +133.3% |
| Q2 2017 | $337,000 | -25.3% | 17,215 | -10.4% | 0.00% | -25.0% |
| Q1 2017 | $451,000 | -38.6% | 19,209 | -67.9% | 0.00% | -33.3% |
| Q4 2016 | $734,000 | +75.6% | 59,819 | +145.8% | 0.01% | +50.0% |
| Q3 2016 | $418,000 | +77.1% | 24,337 | +41.7% | 0.00% | +100.0% |
| Q1 2016 | $236,000 | +105.2% | 17,178 | +151.2% | 0.00% | +100.0% |
| Q4 2015 | $115,000 | -68.0% | 6,839 | -70.5% | 0.00% | -50.0% |
| Q4 2014 | $359,000 | +54.1% | 23,191 | +20.4% | 0.00% | +100.0% |
| Q3 2014 | $233,000 | +35.5% | 19,268 | +43.7% | 0.00% | 0.0% |
| Q2 2014 | $172,000 | -55.4% | 13,413 | -63.7% | 0.00% | -50.0% |
| Q3 2013 | $386,000 | – | 36,931 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |